

TRIPOD Checklist: Prediction Model Development and Validation

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	D;V Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2
Introduction			
Background and objectives	3a	D;V Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	3
	3b	D;V Specify the objectives, including whether the study describes the development or validation of the model or both.	4
Methods			
Source of data	4a	D;V Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	4
	4b	D;V Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	4
Participants	5a	D;V Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	4
	5b	D;V Describe eligibility criteria for participants.	4
	5c	D;V Give details of treatments received, if relevant.	NA
Outcome	6a	D;V Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	4
	6b	D;V Report any actions to blind assessment of the outcome to be predicted.	N/A
Predictors	7a	D;V Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	5
	7b	D;V Report any actions to blind assessment of predictors for the outcome and other predictors.	N/A
Sample size	8	D;V Explain how the study size was arrived at.	4, 6
Missing data	9	D;V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	6
Statistical analysis methods	10a	D Describe how predictors were handled in the analyses.	6-7
	10b	D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	6-7
	10c	V For validation, describe how the predictions were calculated.	6-7
	10d	D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models.	7
	10e	V Describe any model updating (e.g., recalibration) arising from the validation, if done.	6-7
Risk groups	11	D;V Provide details on how risk groups were created, if done.	NA
Development vs. validation	12	V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	6-7
Results			
Participants	13a	D;V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	7, 19
	13b	D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	7
	13c	V For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	7, 15
Model development	14a	D Specify the number of participants and outcome events in each analysis.	7
	14b	D If done, report the unadjusted association between each candidate predictor and outcome.	7
Model specification	15a	D Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	8, 17
	15b	D Explain how to use the prediction model.	10
Model performance	16	D;V Report performance measures (with CIs) for the prediction model.	8, 17
Model-updating	17	V If done, report the results from any model updating (i.e., model specification, model performance).	N/A
Discussion			
Limitations	18	D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	9
Interpretation	19a	V For validation, discuss the results with reference to performance in the development data, and any other validation data.	9, 10
	19b	D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	9, 10
Implications	20	D;V Discuss the potential clinical use of the model and implications for future research.	10
Other information			
Supplementary information	21	D;V Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	NA
Funding	22	D;V Give the source of funding and the role of the funders for the present study.	1

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.